FPR1 and acquired epidermolysis bullosa: Furthermore, we recognized and experimentally validated novel gene interaction partners of SYK, specifically Fpr1 and Plaur. This should encourage the exploitation of SYK and SYK-regulated genes as potential therapeutic targets for EBA, as well as diseases with autoantibody-driven pathology.